Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Work In Process (2022 - 2025)

Historic Work In Process for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to $4.7 million.

  • Arcutis Biotherapeutics' Work In Process rose 16515.15% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year increase of 16515.15%. This contributed to the annual value of $584000.0 for FY2024, which is 2016.46% up from last year.
  • As of Q3 2025, Arcutis Biotherapeutics' Work In Process stood at $4.7 million, which was up 16515.15% from $1.7 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year Work In Process high stood at $4.7 million for Q3 2025, and its period low was $116000.0 during Q3 2022.
  • In the last 4 years, Arcutis Biotherapeutics' Work In Process had a median value of $584000.0 in 2024 and averaged $1.2 million.
  • Its Work In Process has fluctuated over the past 5 years, first surged by 115846.99% in 2024, then tumbled by 6600.09% in 2025.
  • Quarter analysis of 4 years shows Arcutis Biotherapeutics' Work In Process stood at $395000.0 in 2022, then grew by 23.04% to $486000.0 in 2023, then increased by 20.16% to $584000.0 in 2024, then soared by 709.08% to $4.7 million in 2025.
  • Its Work In Process stands at $4.7 million for Q3 2025, versus $1.7 million for Q2 2025 and $783000.0 for Q1 2025.